Results of the primary treatment in T1-3M0 prostatic adenocarcinoma are dependent on tumour biology.
The results of the primary treatment were analysed in relation to biological prognostic factors in a series of 215 males with T1-3M0 prostatic adenocarcinoma. T-category, Gleason score and DNA ploidy were significantly related to progression-free survival and overall survival. Incidental tumours usually had a favorable prognosis, 86% of them being diploid, whereas the incidental aneuploid tumours (14%) ran an unfavorable course. In clinically malignant prostates (TPR), neither Gleason score nor DNA ploidy had prognostic significance. The treatment had prognostic significance only in diploid tumours or in tumours with Gleason score value < or = 7, while aneuploid tumours or tumours with Gleason score value > 7 always had unfavorable prognosis irrespective of treatment. Tumours treated by radical prostatectomy or by radical radiation treatment were associated with a favorable prognosis, as contrasted to the tumours treated by endocrine treatment or those followed-up only, which had a high rate of mortality. Transurethral resection was weakly related to increased risk of death from prostatic adenocarcinoma, although the basic mechanisms behind this observation remain to be explained.
Vesalainen
S
S
Department Surgery, University of Kuopio, Finland.
Lipponen
P
P
Nordling
S
S
Talja
M
M
Syrjänen
K
K
D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000782:Aneuploidy; D004273:DNA, Neoplasm / Q000032:analysis; D018450:Disease Progression; D018572:Disease-Free Survival; D004967:Estrogens / Q000627:therapeutic use*; D005387:Finland / Q000453:epidemiology; D005500:Follow-Up Studies; D006801:Humans; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009919:Orchiectomy; D011379:Prognosis; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis; D016896:Treatment Outcome
D004273:DNA, Neoplasm; D004967:Estrogens